|
|
||||||||
Neurology, Vol 45, Issue 7 1268-1276, Copyright © 1995 by American Academy of Neurology
ARTICLES |
KP Johnson, BR Brooks, JA Cohen, CC Ford, J Goldstein, RP Lisak, LW Myers, HS Panitch, JW Rose and RB Schiffer
Department of Neurology, University of Maryland, Baltimore, USA.
We studied copolymer 1 (Copaxone) in a multicenter (11-university) phase III trial of patients with relapsing-remitting multiple sclerosis (MS). Two hundred fifty-one patients were randomized to receive copolymer 1 (n = 125) or placebo (n = 126) at a dosage of 20 mg by daily subcutaneous injection for 2 years. The primary end point was a difference in the MS relapse rate. The final 2-year relapse rate was 1.19 +/- 0.13 for patients receiving copolymer 1 and 1.68 +/- 0.13 for those receiving placebo, a 29% reduction in favor of copolymer 1 (p = 0.007) (annualized rates = 0.59 for copolymer 1 and 0.84 for placebo). Trends in the proportion of relapse-free patients and median time to first relapse favored copolymer 1. Disability was measured by the Expanded Disability Status Scale (EDSS), using a two-neurologist (examining and treating) protocol. When the proportion of patients who improved, were unchanged, or worsened by > or = 1 EDSS step from baseline to conclusion (2 years) was evaluated, significantly more patients receiving copolymer 1 were found to have improved and more receiving placebo worsened (p = 0.037). Patient withdrawals were 19 (15.2%) from the copolymer 1 group and 17 (13.5%) from the placebo group at approximately the same intervals. The treatment was well tolerated. The most common adverse experience was an injection-site reaction. Rarely, a transient self-limited systemic reaction followed the injection in 15.2% of those receiving copolymer 1 and 3.2% of those receiving placebo.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
![]() |
P. Borel, M. Benkhoucha, M. S. Weber, S. S. Zamvil, M.-L. Santiago-Raber, and P. H. Lalive Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model Int. Immunol., October 1, 2008; 20(10): 1313 - 1319. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R Korenke, M. P Rivey, and D. R Allington Sustained-Release Fampridine for Symptomatic Treatment of Multiple Sclerosis Ann. Pharmacother., October 1, 2008; 42(10): 1458 - 1465. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Goodin, B. A. Cohen, P. O'Connor, L. Kappos, and J. C. Stevens Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, September 2, 2008; 71(10): 766 - 773. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. C. Ebers, L. Heigenhauser, M. Daumer, C. Lederer, and J. H. Noseworthy Disability as an outcome in MS clinical trials Neurology, August 26, 2008; 71(9): 624 - 631. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hestvik, G Skorstad, D. Price, F Vartdal, and T Holmoy Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid Multiple Sclerosis, July 1, 2008; 14(6): 749 - 758. [Abstract] [PDF] |
||||
![]() |
J Petkau, S. Reingold, U Held, G. Cutter, T. Fleming, M. Hughes, D. Miller, H. McFarland, and J. Wolinsky Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses Multiple Sclerosis, July 1, 2008; 14(6): 770 - 778. [Abstract] [PDF] |
||||
![]() |
T Vollmer, H Panitch, A Bar-Or, J Dunn, M. Freedman, S. Gazda, D Campagnolo, F Deutsch, and D. Arnold Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis Multiple Sclerosis, June 1, 2008; 14(5): 663 - 670. [Abstract] [PDF] |
||||
![]() |
J. Cohen, P. Calabresi, S. Chakraborty, K. Edwards, T. Eickenhorst, W. Felton III, E. Fisher, R. Fox, A. Goodman, C. Hara-Cleaver, et al. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data Multiple Sclerosis, April 1, 2008; 14(3): 370 - 382. [Abstract] [PDF] |
||||
![]() |
C. H. Polman, S. C. Reingold, F. Barkhof, P. A. Calabresi, M. Clanet, J. A. Cohen, G. R. Cutter, M. S. Freedman, L. Kappos, F. D. Lublin, et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment Neurology, March 25, 2008; 70(13_Part_2): 1134 - 1140. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhao, A. Traboulsee, A. J. Petkau, and D. Li Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis Neurology, March 25, 2008; 70(13_Part_2): 1092 - 1097. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Hauser, E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal, et al. B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis N. Engl. J. Med., February 14, 2008; 358(7): 676 - 688. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.L. Tremlett and J. Oger Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective Multiple Sclerosis, January 1, 2008; 14(1): 94 - 105. [Abstract] [PDF] |
||||
![]() |
B.R. Sajja, P.A. Narayana, J.S. Wolinsky, C.W. Ahn, and t. P. T. M. G. N/A Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study Multiple Sclerosis, January 1, 2008; 14(1): 73 - 80. [Abstract] [PDF] |
||||
![]() |
M. G. Brown, S. Kirby, C. Skedgel, J. D. Fisk, T. J. Murray, V. Bhan, and I. S. Sketris How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology, October 9, 2007; 69(15): 1498 - 1507. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Thouvenot, D. Hillaire-Buys, M.A. Bos-Thompson, V. Rigau, L. Durand, B. Guillot, and W. Camu Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis Multiple Sclerosis, August 1, 2007; 13(7): 941 - 944. [Abstract] [PDF] |
||||
![]() |
L. Glass-Marmor, T. Paperna, Y. Ben-Yosef, and A. Miller Chronotherapy using corticosteroids for multiple sclerosis relapses J. Neurol. Neurosurg. Psychiatry, August 1, 2007; 78(8): 886 - 888. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kobayashi, H. Kobayashi, L. Gu, T. Malefyt, and T. J. Siahaan Antigen-Specific Suppression of Experimental Autoimmune Encephalomyelitis by a Novel Bifunctional Peptide Inhibitor J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 879 - 886. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Coyle Evidence-based medicine and clinical trials Neurology, June 12, 2007; 68(24_suppl_4): S3 - S7. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Khan Can clinical outcomes be used to detect neuroprotection in multiple sclerosis? Neurology, May 29, 2007; 68(22_suppl_3): S64 - S71. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rovaris, G. Comi, M. Rocca, P. Valsasina, D. Ladkani, E. Pieri, S. Weiss, G. Shifroni, J. Wolinsky, M. Filippi, et al. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial Multiple Sclerosis, May 1, 2007; 13(4): 502 - 508. [Abstract] [PDF] |
||||
![]() |
F. Blanchette Clinical significance of glatiramer acetate antibodies Multiple Sclerosis, May 1, 2007; 13(1_suppl): 28 - 35. [Abstract] [PDF] |
||||
![]() |
D. Pohl, E. Waubant, B. Banwell, D. Chabas, T. Chitnis, B. Weinstock-Guttman, S. Tenembaum, and for the International Pediatric MS Study Group Treatment of pediatric multiple sclerosis and variants Neurology, April 17, 2007; 68(16_suppl_2): S54 - S65. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Cohen, M. Rovaris, A. D. Goodman, D. Ladkani, D. Wynn, M. Filippi, and for the 9006 Study Group Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS Neurology, March 20, 2007; 68(12): 939 - 944. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Turley and S. D. Miller Peripheral Tolerance Induction Using Ethylenecarbodiimide-Fixed APCs Uses both Direct and Indirect Mechanisms of Antigen Presentation for Prevention of Experimental Autoimmune Encephalomyelitis J. Immunol., February 15, 2007; 178(4): 2212 - 2220. [Abstract] [Full Text] [PDF] |
||||
![]() |
O Lily, E McFadden, E Hensor, M Johnson, and H Ford Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment Multiple Sclerosis, November 1, 2006; 12(6): 808 - 813. [Abstract] [PDF] |
||||
![]() |
S Martinez-Yelamos, A Martinez-Yelamos, G M. Ozaeta, V Casado, O Carmona, and T. Arbizu Regression to the mean in multiple sclerosis Multiple Sclerosis, November 1, 2006; 12(6): 826 - 829. [Abstract] [PDF] |
||||
![]() |
J. H. Noseworthy How much can we learn from long-term extension trials in multiple sclerosis? Neurology, September 26, 2006; 67(6): 930 - 931. [Full Text] [PDF] |
||||
![]() |
H. Tremlett and V. Devonshire Is late-onset multiple sclerosis associated with a worse outcome? Neurology, September 26, 2006; 67(6): 954 - 959. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Kappos, J. Antel, G. Comi, X. Montalban, P. O'Connor, C. H. Polman, T. Haas, A. A. Korn, G. Karlsson, E. W. Radue, et al. Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis N. Engl. J. Med., September 14, 2006; 355(11): 1124 - 1140. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Trojano, P. Russo, A. Fuiani, D. Paolicelli, E. Di Monte, E. Granieri, G. Rosati, G. Savettieri, G. Comi, P. Livrea, et al. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFN{beta} exposure in multiple sclerosis Multiple Sclerosis, September 1, 2006; 12(5): 578 - 585. [Abstract] [PDF] |
||||
![]() |
M. A. Friese, X. Montalban, N. Willcox, J. I. Bell, R. Martin, and L. Fugger The value of animal models for drug development in multiple sclerosis Brain, August 1, 2006; 129(8): 1940 - 1952. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Sorensen, N. Koch-Henriksen, M. Ravnborg, J. L. Frederiksen, K a. Jensen, A. Heltberg, H. Schaldemose, S. Deth, O l. Kristensen, M. Worm, et al. Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey Multiple Sclerosis, June 1, 2006; 12(3): 253 - 264. [Abstract] [PDF] |
||||
![]() |
C C Ford, K P Johnson, R P Lisak, H S Panitch, G Shifroni, J S Wolinsky, and The Copaxone(R) Study Group A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients Multiple Sclerosis, June 1, 2006; 12(3): 309 - 320. [Abstract] [PDF] |
||||
![]() |
D. K. Tennakoon, R. S. Mehta, S. B. Ortega, V. Bhoj, M. K. Racke, and N. J. Karandikar Therapeutic Induction of Regulatory, Cytotoxic CD8+ T Cells in Multiple Sclerosis. J. Immunol., June 1, 2006; 176(11): 7119 - 7129. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. Gordon, C. Doorish, J. Montes, R. L. Mosley, B. Diamond, R. B. MacArthur, L. H. Weimer, P. Kaufmann, A. P. Hays, L. P. Rowland, et al. Randomized controlled phase II trial of glatiramer acetate in ALS Neurology, April 11, 2006; 66(7): 1117 - 1119. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Pittock, B. G. Weinshenker, J. H. Noseworthy, C. F. Lucchinetti, M. Keegan, D. M. Wingerchuk, J. Carter, E. Shuster, and M. Rodriguez Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol, April 1, 2006; 63(4): 611 - 614. [Full Text] [PDF] |
||||
![]() |
E. M. Frohman, E. Havrdova, F. Lublin, F. Barkhof, A. Achiron, M. K. Sharief, O. Stuve, M. K. Racke, L. Steinman, H. Weiner, et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol, April 1, 2006; 63(4): 614 - 619. [Full Text] [PDF] |
||||
![]() |
Y. Jee, R. Liu, X.-F. Bai, D. I. Campagnolo, F.-D. Shi, and T. L. Vollmer Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis? Int. Immunol., April 1, 2006; 18(4): 537 - 544. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Polman, P. W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, J. T. Phillips, F. D. Lublin, G. Giovannoni, A. Wajgt, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med., March 2, 2006; 354(9): 899 - 910. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Rudick, W. H. Stuart, P. A. Calabresi, C. Confavreux, S. L. Galetta, E.-W. Radue, F. D. Lublin, B. Weinstock-Guttman, D. R. Wynn, F. Lynn, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med., March 2, 2006; 354(9): 911 - 923. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kremenchutzky, G. P. A. Rice, J. Baskerville, D. M. Wingerchuk, and G. C. Ebers The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease Brain, March 1, 2006; 129(3): 584 - 594. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Racke, A. R. Gocke, M. Muir, A. Diab, P. D. Drew, and A. E. Lovett-Racke Nuclear Receptors and Autoimmune Disease: The Potential of PPAR Agonists to Treat Multiple Sclerosis J. Nutr., March 1, 2006; 136(3): 700 - 703. [Abstract] [Full Text] [PDF] |
||||
![]() |
S L Minden, D Frankel, L Hadden, J Perloff, K P Srinath, and D C Hoaglin The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics Multiple Sclerosis, February 1, 2006; 12(1): 24 - 38. [Abstract] [PDF] |
||||
![]() |
W. Pollmann, L.-P. Erasmus, W. Feneberg, and A. Straube The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS Neurology, January 24, 2006; 66(2): 275 - 277. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Held, L. Heigenhauser, C. Shang, L. Kappos, C. Polman, and for the Sylvia Lawry Centre for MS Research Predictors of relapse rate in MS clinical trials Neurology, December 13, 2005; 65(11): 1769 - 1773. [Abstract] [Full Text] [PDF] |
||||
![]() |
R A Rudick, G R Cutter, M Baier, B Weinstock-Guttman, M K Mass, E Fisher, D M Miller, and A W Sandrock Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients Multiple Sclerosis, December 1, 2005; 11(6): 626 - 634. [Abstract] [PDF] |
||||
![]() |
J Haas, M Maas-Enriquez, and H P Hartung Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis - results of a retrospective multicenter observational study over five years Multiple Sclerosis, October 1, 2005; 11(5): 562 - 567. [Abstract] [PDF] |
||||
![]() |
E. M. Frohman, O. Stuve, E. Havrdova, J. Corboy, A. Achiron, R. Zivadinov, P. S. Sorensen, J. T. Phillips, B. Weinshenker, K. Hawker, et al. Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations Arch Neurol, October 1, 2005; 62(10): 1519 - 1530. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Zajicek Diagnosis and disease modifying treatments in multiple sclerosis Postgrad. Med. J., September 1, 2005; 81(959): 556 - 561. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Ghezzi, M P Amato, M Capobianco, P Gallo, G Marrosu, V Martinelli, N Milani, C Milanese, L Moiola, F Patti, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study Multiple Sclerosis, August 1, 2005; 11(4): 420 - 424. [Abstract] [PDF] |
||||
![]() |
C. E. Smith, T. N. Eagar, J. L. Strominger, and S. D. Miller Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis PNAS, July 5, 2005; 102(27): 9595 - 9600. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R Jeffery, N. Chepuri, D. Durden, and J. Burdette A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging Multiple Sclerosis, June 1, 2005; 11(3): 296 - 301. [Abstract] [PDF] |
||||
![]() |
J. Rio, J. Porcel, N. Tellez, A. Sanchez-Betancourt, M a. Tintore, M J. Arevalo, C. Nos, and X. Montalban Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis Multiple Sclerosis, June 1, 2005; 11(3): 306 - 309. [Abstract] [PDF] |
||||
![]() |
N. J. Karandikar and M. K. Racke Glatiramer Acetate Therapy: The Plot Thickens Arch Neurol, June 1, 2005; 62(6): 858 - 859. [Full Text] [PDF] |
||||
![]() |
S Nolden, C Casper, A Kuhn, and H F Petereit Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate Multiple Sclerosis, April 1, 2005; 11(2): 245 - 248. [Abstract] [PDF] |
||||
![]() |
C. D. Margot, M. L. Ford, and B. D. Evavold Amelioration of Established Experimental Autoimmune Encephalomyelitis by an MHC Anchor-Substituted Variant of Proteolipid Protein 139-151 J. Immunol., March 15, 2005; 174(6): 3352 - 3358. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Blair, M. E. Pease, J. Hammond, D. Valenta, J. Kielczewski, H. Levkovitch-Verbin, and H. Quigley Effect of Glatiramer Acetate on Primary and Secondary Degeneration of Retinal Ganglion Cells in the Rat Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 884 - 890. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. H. Stern, Z. Illes, J. Reddy, D. B. Keskin, M. Fridkis-Hareli, V. K. Kuchroo, and J. L. Strominger Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis PNAS, February 1, 2005; 102(5): 1620 - 1625. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Cohen, O. Khan, D. R. Jeffery, K. Bashir, S. A. Rizvi, E. J. Fox, M. Agius, R. Bashir, T. E. Collins, R. Herndon, et al. Identifying and treating patients with suboptimal responses Neurology, December 28, 2004; 63(12_suppl_6): S33 - S40. [Abstract] [Full Text] |
||||
![]() |
W. H. Stuart Current clinical perspectives on the treatment of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S1 - S2. [Full Text] |
||||
|
|